在生物类似药的市场透中,需求与供应侧政策:哪一个更有效?
Gyeongseon Shin1, Heejin Han2, Gyeyoung Choi2
1College of Pharmacy, Ewha Womans University, Seoul, South Korea. sunny628@ewha.ac.kr.
概括
需求侧政策显著促进生物类似药的采用和市场份额. 政策制定者应该优先考虑这些战略,就像财政激励一样,以有效地降低医疗保健成本并增加生物类似药的使用.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 进入市场 进入市场 进入市场
背景情况:
- 在高收入国家,生物类似药的吸收率有很大差异.
- 了解政策影响对于优化生物类药物市场透至关重要.
研究的目的:
- 评估需求和供给侧政策对生物类似药物市场透的影响.
- 确定有效的战略,以促进生物类似药在八个高收入国家采用.
主要方法:
- 对欧洲和亚洲国家关键生物制剂的生物类似药市场透率 (市场份额,时间到50%的份额) 的分析.
- 需求和供给侧政策的分类和权重.
- 斯皮尔曼相关性用于评估政策透关系.
主要成果:
- 强有力的需求侧政策的国家 (例如,瑞典,意大利,英国) 显示出更高的生物类似药市场份额和更快的普及率.
- 需求侧政策与增加的市场份额 (rs=0.69) 和减少占有多数份额的时间 (rs=-0.62) 密切相关.
- 供给侧政策显示,与生物类似药物透的关联较弱.
结论:
- 需求侧政策是快速和广泛采用生物类似药的关键驱动力.
- 政策制定者应该优先考虑需求侧措施,以提高生物类似药的吸收并实现医疗保健节省.
相关概念视频
Bioequivalence: Overview
880
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
880
Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
Biopharmaceutics and Pharmacokinetics: Overview
1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
155
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
155
Factors Influencing Bioavailability: First-Pass Elimination
5.8K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
5.8K
Drug Control Governance: Regulatory Bodies and Their Impact
123
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
123


